Half-Year 2022 Financial and Clinical Trials Update
Tecentriq
Anti-PD-L1 cancer immunotherapy - renal cell cancer
Indication
Adjuvant renal cell carcinoma (RCC)
Roche
Advanced renal cell carcinoma (RCC) after immune checkpoint inhibitor
treatment
Phase III
IMmotion010
Phase/study
# of patients
ARM A: Tecentriq monotherapy
ARM B: Placebo
Design
N=778
Primary endpoint
■ Investigator-assessed disease-free survival
Status
CT Identifier
☐
Phase III
Contact-031
N=500
ARM A: Tecentriq plus cabozantinib
ARM B: Cabozantinib
■ Progression-free survival and overall survival
FPI Q1 2017
Recruitment completed Q1 2019
Study did not meet its primary endpoint of DFS Q2 2022
FPI Q3 2020
Recruitment completed Q4 2021
1In collaboration with Exelixis
PD-L1-Programmed cell death-ligand 1; DFS=Disease-free survival
NCT03024996
NCT04338269
92
OncologyView entire presentation